2026-10-10T06:31:21Z https://api.figshare.com/v2/oai

oai:figshare.com:article/34040817 2026-10-01T07:21:06Z category_37339 category_37363 category_37366 portal_1012 item_type_6 month_year_10_2026

Supplementary Table S5 from A Randomized, Nivolumab-Controlled, Phase II Biomarker Study of Lomvastomig and Tobemstomig in Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus Lucjan Wyrwicz (15043971) Arunee Dechaphunkul (15039699) Jong-Seok Lee (15122127) Anthony Turpin (15050195) Aleksandr Sultanbaev (25154346) Min Hee Hong (15014541) Christelle De La Fouchardière (25154349) Maria Alsina (21718246) Tamara Sauri (25154352) Fredrick Asirwa (25154355) Simon Pernot (25154358) Sanghee Cho (15052235) Mansoor Saleh (25154361) Francesca Bergamo (15352527) Romain Cohen (15017486) Lene Baeksgaard (25154364) Florian Lordick (25154367) Dominik Kraus (24317502) Christian Heichinger (24317505) Vu-Long Tran (24317508) Merlind Mücke (24317511) Francesca Michielin (17314282) Christine McIntyre (24317514) Kate Madden-Raja (24317517) Daniel Marbach (15131009) Iakov I. Davydov (24317520) Rui Lopes (19537724) Sabine Wilson (24317526) Tobias Rutishauser (24317529) Laura Codarri Deak (24317532) Henry Kao (18366343) Christoph Markert (24317487) Sung-Bae Kim (15033090) Cancer Immuno-oncology Clinical Research and Trials Clinical Trial Results Phase II clinical trials Gastrointestinal Cancers Esophageal cancer Immunotherapy Checkpoint blockade <p>Summary of key pharmacokinetic parameters</p> 2026-10-01T00:00:00Z Text Journal contribution 10.1158/1078-0432.34040817 https://figshare.com/articles/journal_contribution/Supplementary_Table_S5_from_A_Randomized_Nivolumab-Controlled_Phase_II_Biomarker_Study_of_Lomvastomig_and_Tobemstomig_in_Advanced_or_Metastatic_Squamous_Cell_Carcinoma_of_the_Esophagus/34040817 CC BY